A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

December 1, 2022

Study Completion Date

June 1, 2023

Conditions

The Primary Study Metric is Progression-free Survival (PFS)

All Listed Sponsors

lead

Laibin People's Hospital

OTHER

NCT05934461 - A Retrospective Study of Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant Lung Cancer | Biotech Hunter | Biotech Hunter